ArticleScientific reports2025
Temporal subtypes and characteristics of insomnia treatment responses.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
This study aims to identify specific characteristics that can predict the treatment efficacy and onset time in patients with insomnia. A retrospective study was conducted on patients who visited the Sleep Disorders Clinic between January 1, 2016, and October 19, 2024 and underwent digital CBT-I. Data on demographic characteristics, Pittsburgh Sleep Quality Index (PSQI), Generalized Anxiety Disorder Scale (GAD-7), Patient Health Questionnaire (PHQ-9), Somatic Symptom Questionnaire (PHQ-15), Epworth Sleepiness Scale (ESS), and Eysenck Personality Questionnaire (EPQ) were collected. The PSQI score reduction rate was used as an indicator of treatment efficacy, where a reduction rate of more than 25% was generally considered effective. Since patients in this study underwent multiple assessments and exhibited varying degrees of treatment response, the average reduction rate was ultimately used to determine treatment effectiveness within this time dimension. Based on the time dimension, patients (N = 834) were categorized into two groups: the early-response group (≤ 8 weeks) and the late-response group (> 8 weeks or non-responsive). The demographic characteristics and scale data of 834 patients indicated no significant differences between the two groups in terms of gender (P = 0.491), family history of insomnia (P = 0.167), and ESS score (P = 0.949). However, significant differences were observed between the two groups in age (P = 0.005), education level (P < 0.001), duration of insomnia (P < 0.001), GAD-7 score (P = 0.031), PHQ-9 score (P = 0.044), and neuroticism personality trait (P = 0.039). The late-response group had a higher mean age, a lower education level, and a longer duration of insomnia than the early-response group. Additionally, the late-response group exhibited lower GAD-7, PHQ-9, and neuroticism personality trait scores compared to the early-response group. Multivariate logistic regression analysis indicated that higher education level (college or above), higher PHQ-9 and PHQ-15 scores, and a neuroticism personality trait were significant predictors of better treatment response and earlier onset of efficacy in insomnia patients. A longer duration of insomnia was identified as a risk factor for poor treatment response and delayed onset of efficacy. Conclusion: Insomnia patients with higher education levels (college or above), higher PHQ-9 and PHQ-15 scores, and a neuroticism personality trait tend to have better treatment outcomes and an earlier onset of efficacy. Longer duration of insomnia, tend to experience poorer treatment outcomes and a delayed response to treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.